24 Results

People

  1. Korde
    Korde
  2. Lesokhin
    Lesokhin
  3. Hassoun
    Hassoun
  4. Chung
    Chung
  5. Giralt
    Giralt
  6. Landau
    Landau
  7. Mailankody
    Mailankody
  8. Hultcrantz
    Hultcrantz
  9. Scordo
    Scordo
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (24)
  2. Department of Medicine (24)
  3. Hematologic Malignancies Research (24)
  4. Hematologic Malignancies, Division of (24)
  5. Myeloma (24)
  6. Survivorship Research (24)
  7. Bone Marrow Transplant (20)
  8. Sloan Kettering Institute Postdocs (19)
  9. CTCR Scholars (18)
  10. Epidemiology and Biostatistics (16)
  1. "Hematologic Malignancies Research"
  2. "Ahmet Dogan"
  3. "Neha Korde"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (6)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (24)
  2. Department of Medicine (24)
  3. Hematologic Malignancies Research (24)
  4. Hematologic Malignancies, Division of (24)
  5. Myeloma (24)
  6. Survivorship Research (24)

More Groups

People
  1. Ahmet Dogan (24)
  2. Alexander Lesokhin (24)
  3. Neha Korde (24)
  4. Hani Hassoun (21)
  5. David Chung (20)
  6. Heather Landau (20)

More People

Years
  1. 2023 (5)
  2. 2022 (3)
  3. 2021 (5)
  4. 2020 (4)
  5. 2019 (2)
  6. 2018 (2)

More Years

Publications
  1. Blood (15)
  2. Clinical Lymphoma, Myeloma and Leukemia (2)
  3. American Journal of Hematology (1)
  4. Biology of Blood and Marrow Transplantation (1)
  5. JAMA Oncology (1)
  6. Leukemia and Lymphoma (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. Elsevier Inc. (3)
  3. American Medical Association (1)
  4. Elsevier Science, Inc. (1)
  5. John Wiley & Sons, Inc. (1)
  6. Nature Publishing Group (1)

More Publishers

Results (24)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revealing novel mechanisms underlying inactivation of tumor suppressor genes on duplicated chromosomes in multiple myeloma
    Meeting Abstract

    Cirrincione, A.; Kaddoura, M.; Poos, A. M.; Ziccheddu, B.; Maclachlan, K. H.; Chojnacka, M.; Diamond, B.; Blaney, P.; Gagler, D.; Zhang, Y.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Tracking the earliest genomic events in multiple myeloma life-history
    Meeting Abstract

    Cirrincione, A.; Poos, A.; Kaddoura, M.; Ziccheddu, B.; Maclachlan, K.; Chojnacka, M.; Diamond, B.; Papadimitriou, M.; Blaney, P.; Gagler, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Tracking the earliest genomic events in multiple myeloma life-history
    Meeting Abstract

    Cirrincione, A.; Ziccheddu, B.; Maclachlan, K. H.; Poos, A. M.; Chojnacka, M.; Diamond, B.; Boyle, E. M.; Blaney, P.; Gagler, D.; Zhang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save